Settings
RNN [AMEX]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.11 Insider Own3.70% Shs Outstand178.06M Perf Week2.74%
Market Cap129.98M Forward P/E- EPS next Y-0.10 Insider Trans-8.75% Shs Float156.18M Perf Month2.82%
Income-19.00M PEG- EPS next Q-0.02 Inst Own8.10% Short Float3.44% Perf Quarter-1.34%
Sales- P/S- EPS this Y-16.70% Inst Trans0.01% Short Ratio5.32 Perf Half Y-2.67%
Book/sh0.16 P/B4.56 EPS next Y9.10% ROA-55.70% Target Price3.25 Perf Year-38.14%
Cash/sh0.20 P/C3.65 EPS next 5Y- ROE-76.40% 52W Range0.65 - 1.52 Perf YTD4.29%
Dividend- P/FCF- EPS past 5Y4.90% ROI- 52W High-51.97% Beta1.03
Dividend %- Quick Ratio21.40 Sales past 5Y- Gross Margin- 52W Low12.31% ATR0.04
Employees16 Current Ratio21.40 Sales Q/Q- Oper. Margin- RSI (14)47.78 Volatility4.71% 6.62%
OptionableNo Debt/Eq0.00 EPS Q/Q50.00% Profit Margin- Rel Volume0.47 Prev Close0.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.01M Price0.73
Recom2.00 SMA20-5.20% SMA50-0.44% SMA200-6.90% Volume471,635 Change-0.54%
Dec-28-12Initiated Burrill Institutional Research Mkt Outperform $1
Jan-18-12Resumed Rodman & Renshaw Mkt Perform
Jun-16-11Resumed Brean Murray Buy $3
Dec-02-10Initiated Brean Murray Buy $3
Jan-07-15 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase(TM) 2015 GlobeNewswire +5.96%
Jan-06-15 09:00AM  Rexahn Pharmaceuticals Announces Publication of Preclinical Data for RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells GlobeNewswire
Dec-10-14 05:46AM  Why Rexahn Pharmaceuticals (RNN) Could Be Positioned for a Surge? Zacks
Dec-09-14 07:39AM  Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% Zacks
Dec-05-14 05:48AM  Rexahn Pharmaceuticals (RNN): Strong Industry, Solid Earnings Estimate Revisions Zacks
Dec-04-14 09:00AM  Rexahn Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 10, 2014 GlobeNewswire
Dec-03-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
09:00AM  Rexahn Pharmaceuticals Appoints Richard Rodgers to Its Board of Directors GlobeNewswire
Nov-21-14 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
Nov-17-14 09:00AM  Rexahn Pharmaceuticals to Participate in Brean Capital 2014 Life Sciences Summit GlobeNewswire
Nov-14-14 07:09PM  10-Q for Rexahn Pharmaceuticals, Inc. Company Spotlight
Nov-13-14 09:18AM  Rexahn posts 3Q loss AP
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results and Pipeline Update GlobeNewswire
Nov-12-14 04:33PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-11-14 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference on November 18, 2014 GlobeNewswire
Oct-28-14 09:00AM  Rexahn Pharmaceuticals to Present at the BIO-Europe(R) Conference in Frankfurt, Germany GlobeNewswire
Oct-03-14 04:24PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
Sep-30-14 09:00AM  Rexahn Pharmaceuticals to Present at 13th Annual BIO Investor Forum GlobeNewswire
Sep-26-14 07:54AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% Zacks
Sep-24-14 04:30PM  Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer GlobeNewswire
Sep-23-14 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland GlobeNewswire
Sep-16-14 09:00AM  Rexahn Pharmaceuticals to Present at the BioPharm America 2014 in Boston, Massachusetts, USA Business Wire
Sep-04-14 09:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference on September 9, 2014 Business Wire +7.79%
06:48AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Rises 9.6% Zacks
Sep-03-14 09:00AM  Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform Business Wire +10.00%
Aug-14-14 09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results and Pipeline Update Business Wire -5.48%
Aug-13-14 04:33PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-18-14 09:00AM  Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors Business Wire
Jun-16-14 06:52AM  What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) Zacks
Jun-09-14 04:21PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
May-23-14 04:41PM  Rexahn files $150M mixed securities shelf at theflyonthewall.com
May-16-14 08:25AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% Zacks
May-15-14 09:08AM  Rexahn sees cash, cash equivalents balance sufficient to fund company into 1H16 at theflyonthewall.com +19.77%
09:06AM  Rexahn reports Q1 EPS (9c), consensus (2c) at theflyonthewall.com
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update Business Wire
May-14-14 05:08PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online +8.86%
05:07PM  Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification at Seeking Alpha
May-08-14 09:04AM  Rexahn announces additional RX-3117 preclinical studies data at theflyonthewall.com
09:00AM  Rexahn Announces Additional Data from Preclinical Studies of RX-3117 Business Wire
Apr-21-14 04:23PM  Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff at Seeking Alpha
09:01AM  Rexahn presents data from preclinical studies of RX-21101 theflyonthewall.com
09:00AM  Rexahn Presents Data from Preclinical Studies of RX-21101 Business Wire
Apr-02-14 09:00AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting Business Wire +12.28%
Mar-24-14 08:15AM  Rexahn sees complete RX-3117 Phase I enrollment in 4Q14-early FY15 theflyonthewall.com
08:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights Business Wire
Mar-21-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Mar-19-14 06:00AM  3 Stocks Under $10 Making Big Moves at TheStreet
Mar-17-14 08:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Business Wire
Mar-15-14 03:15PM  This Week in Biotech: NW Bio Soars While Geron Goes Geronimo at Motley Fool
Mar-12-14 04:30PM  Phase I Data on Rexahn's Supinoxin Zacks
Mar-11-14 02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher at Motley Fool
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors Business Wire
Mar-07-14 10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet -8.33%
Mar-04-14 08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference Business Wire
Mar-03-14 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Optionetics +5.19%
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Business Wire
Feb-27-14 12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket at Seeking Alpha +10.66%
Feb-06-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet +7.77%
Feb-04-14 08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Business Wire
Jan-31-14 02:16PM  Following Unmet Needs To Biotech Profits: Echo He at Seeking Alpha
Jan-27-14 02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3% Zacks
Jan-21-14 04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 at TheStreet
Jan-15-14 03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility at Seeking Alpha -10.34%
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
08:59AM  Rexahn Announces $20 Million Registered Direct Offering Business Wire
08:26AM  3 Biotechs Getting Plenty Of Attention From Investors at Seeking Alpha
Jan-14-14 09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma Business Wire -27.50%
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Jan-10-14 10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today at TheStreet +62.86%
Jan-09-14 04:20PM  Rexahn Pharma rises as analyst starts coverage AP +12.90%
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial at Seeking Alpha
Jan-08-14 08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors Business Wire +5.08%
Jan-07-14 08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 Business Wire +5.36%
Dec-22-13 12:49PM  Rexahn: A Turn Around Story For 2014 at Seeking Alpha
Dec-11-13 08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902) Business Wire +20.00%
Nov-25-13 01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment at Seeking Alpha +5.26%
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ahn Chang HoDirectorJan 12Option Exercise0.8048,44438,7556,058,444Jan 12 06:11 PM
Jeong Tae HeumChief Financial OfficerJan 12Option Exercise0.8049,80039,840554,800Jan 12 06:22 PM
Jeong Tae HeumChief Financial OfficerJan 12Sale0.9149,80045,492505,000Jan 12 06:22 PM
Ahn Chang HoDirectorJan 12Sale0.9148,44444,2636,010,000Jan 12 06:11 PM
Ahn Chang HoDirectorJan 09Option Exercise0.80186,212148,9706,196,212Jan 12 06:11 PM
Jeong Tae HeumChief Financial OfficerJan 09Option Exercise0.80188,690150,952693,690Jan 12 06:22 PM
Jeong Tae HeumChief Financial OfficerJan 09Sale0.92188,690172,708505,000Jan 12 06:22 PM
Ahn Chang HoDirectorJan 09Sale0.92186,212170,4776,010,000Jan 12 06:11 PM
Ahn Chang HoDirectorJan 08Option Exercise0.8080,00064,0006,090,000Jan 12 06:11 PM
Jeong Tae HeumChief Financial OfficerJan 08Option Exercise0.8078,78263,026583,782Jan 12 06:22 PM
Jeong Tae HeumChief Financial OfficerJan 08Sale0.9078,78270,935505,000Jan 12 06:22 PM
Ahn Chang HoDirectorJan 08Sale0.9080,00072,0326,010,000Jan 12 06:11 PM
Ahn Chang HoDirectorJun 12Option Exercise0.80136,193108,9546,950,117Jun 16 07:48 PM
Ahn Chang HoDirectorJun 12Sale0.99136,193134,4366,813,924Jun 16 07:48 PM
McIntosh David MDirectorApr 14Option Exercise0.80125,000100,000125,000Apr 16 04:18 PM